Blinatumomab and pancreatitis: an analysis of FAERS, EudraVigilance, and a large urban U.S. patient population data

Leuk Lymphoma. 2018 Jul;59(7):1759-1761. doi: 10.1080/10428194.2017.1397667. Epub 2017 Nov 8.

Authors

Paras Vakharia¹, Beatrice Nardone¹, William Budris², Kevin Hoshizaki², Olga Frankfurt^{3

4}, Dennis P West^{1

3}

Affiliations

¹ a Department of Dermatology , Northwestern University Feinberg School of Medicine , Chicago , IL , USA.
² b Department of Pharmacy , Northwestern Medicine , Chicago , IL , USA.
³ c Robert H. Lurie Comprehensive Cancer Center, Northwestern University , Chicago , IL , USA.
⁴ d Department of Internal Medicine, Division of Hematology/Oncology , Northwestern University Feinberg School of Medicine , Chicago , IL , USA.

PMID: 29115884
DOI: 10.1080/10428194.2017.1397667

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Antibodies, Bispecific / adverse effects*
Antibodies, Bispecific / therapeutic use
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Antineoplastic Agents, Immunological / adverse effects*
Antineoplastic Agents, Immunological / therapeutic use
Humans
Pancreatitis / epidemiology*
Pancreatitis / etiology*
Population Surveillance
Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology
United States / epidemiology

Substances

Antibodies, Bispecific
Antineoplastic Agents
Antineoplastic Agents, Immunological
blinatumomab

Grants and funding

UL1 TR000150/TR/NCATS NIH HHS/United States